Kristy Mount, MD
Family Medicine · Plainfield, INNPI 1235572124
Payments from drug & device makers
Across 389 payments — averaging $18.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Novo Nordisk$1K
- Lilly USA, LLC$718
- GSK$570
- Novartis$509
- Amgen$501
- plus $2K from 33 others
What the payments were for
- Food & beverage$7,014100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 85 | $1,200 |
| Novo Nordisk | 64 | $1,179 |
| Lilly USA, LLC | 41 | $718 |
| GSK | 25 | $570 |
| Novartis | 21 | $509 |
| Amgen | 26 | $501 |
| Boehringer Ingelheim | 21 | $389 |
| Pfizer | 24 | $383 |
| Exact Sciences | 8 | $172 |
| Astellas Pharma US Inc | 9 | $172 |
| Daiichi Sankyo Inc. | 6 | $129 |
| Merck | 6 | $107 |
| AstraZeneca | 7 | $105 |
| Amarin Pharma, Inc. | 6 | $96 |
| Idorsia Pharmaceuticals US Inc | 5 | $80 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $77 |
| Otsuka America Pharmaceutical, Inc. | 3 | $70 |
| Abbott | 3 | $60 |
| Lundbeck LLC | 2 | $53 |
| Mylan Specialty L.p. | 2 | $42 |
| Ultragenyx Pharmaceutical Inc. | 2 | $40 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $37 |
| Phathom Pharmaceuticals, Inc. | 2 | $36 |
| Axsome Therapeutics, Inc. | 1 | $33 |
| Sanofi-aventis U.S. LLC | 1 | $24 |
| Sumitomo Pharma America, Inc. | 1 | $22 |
| Azurity Pharmaceuticals, Inc. | 1 | $21 |
| Bayer | 1 | $20 |
| Ironwood Pharmaceuticals, Inc | 1 | $19 |
| Cranial Technologies, Inc | 1 | $19 |
| Eisai Inc. | 1 | $18 |
| Smith+Nephew | 1 | $18 |
| Vanda Pharmaceuticals Inc. | 1 | $17 |
| Johnson & Johnson | 1 | $16 |
| Axonics, Inc. | 1 | $16 |
| Collegium Pharmaceutical, Inc. | 1 | $14 |
| Esperion Therapeutics, Inc. | 1 | $14 |
| Teva Pharmaceuticals USA, Inc. | 1 | $11 |
| Shire North American Group Inc | 1 | $11 |
How this compares
$7,014 in reported general payments places this provider in the 90th percentile of 2,709 family medicine providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 148 | $186,100 |
| TrulicityDulaglutide | 47 | $54,261 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 60 | $54,222 |
| EliquisApixaban | 36 | $44,329 |
| FarxigaDapagliflozin Propanediol | 48 | $42,981 |
| JardianceEmpagliflozin | 28 | $37,640 |
| MounjaroTirzepatide | 21 | $20,812 |
| MyrbetriqMirabegron | 23 | $14,616 |
| Spiriva RespimatTiotropium Bromide | 16 | $11,457 |
| Repatha SureclickEvolocumab | 11 | $10,683 |
| Breo ElliptaFluticasone/Vilanterol | 22 | $8,587 |
| Incruse ElliptaUmeclidinium Bromide | 13 | $5,059 |
| Advair HfaFluticasone Propion/Salmeterol | 11 | $4,738 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 39 | $3,715 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 64 | $2,620 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $1,179 | $186,100148 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $718 | $75,07368 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta | $570 | $67,86895 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat | $389 | $49,09744 claims |
| PfizerEliquis | $383 | $44,32936 claims |
| AstraZenecaFarxiga | $105 | $42,98148 claims |
| Astellas Pharma US IncMyrbetriq | $172 | $14,61623 claims |
| AbbVieSynthroid | $1,200 | $1,98534 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,709 family medicine providers in Indiana.
Other family medicine in Plainfield
- Blair BrengleIndianapolis$10.6M
- Laura HelmanMishawaka$4M
- J Christopher SartoreEvansville$3.9M
- Hubert ReyesEvansville$3.2M
- David SchultzEvansville$3M
- Steven SmithIndianapolis$2.5M
- Renee Michelle GalenNewburgh$2.1M
- Eric HewittAvon$1.7M
- Alexander Dela LlanaEvansville$1.6M
- Jonathan ConditMuncie$1.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.